CRMD
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when CorMedix Inc. publishes a filing, an earnings call transcript or a press release.
Get CRMD alertsCorMedix Inc. reported in an 8-K filed September 2, 2025 that Matthew David was appointed Chief Business Officer, effective August 29, 2025. CorMedix Inc. reported in an 8-K filed October 29, 2021 that Matthew David was appointed interim Chief Executive Officer, effective October 4, 2021. The proxy statement of CorMedix Inc. reports total compensation of $1,088,025 for Matthew David in fiscal 2024, including a base salary of $409,125. Disclosed compensation is on record for 6 fiscal years. Matthew David has spoken on 2 earnings calls across 1 company, most recently for CorMedix Inc. on August 7, 2025. CorMedix Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at CorMedix Inc. includes Joseph Todisco (CEO, Chairman and Board Member), Matt David, M.D. (CEO), Matthew David, M.D. (CEO) and 7 others.
“The Company announced today that Susan Blum, Elizabeth Hurlburt and Matthew David (each, an “Executive”) have been appointed to serve as the Company’s Chief Financial Officer, Chief Operating Officer and Chief Business Officer, respectively, each effective as of the Closing Date.”
“As we have discussed, you will serve as the interim Chief Executive Officer of Cormedix Inc. (“Interim CEO”), effective as of October 4, 2021, until such time as Cormedix appoints a new Chief Executive Officer.”
“I'm excited to be here today to provide an overview of our second quarter 2025 financial results as well as an update on CorMedix's cash position and recent financing activities.”
“I’m pleased to be here today to provide an overview of our first quarter 2021 financial results as well as an update on recent financing activity and cash position.”
SEC 8-K
2025-08-29–present
Start not stated–2025-04-28
Last confirmed by a filing; no departure on record
Start not stated–2021-10-29
Last confirmed by a filing; no departure on record
CRMD
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | CorMedix Inc. (CRMD) | Chief Financial Officer | $409,125 | $1,088,025 |
| 2023 | CorMedix Inc. (CRMD) | Chief Financial Officer | $389,135 | $1,031,150 |
| 2022 | CorMedix Inc. (CRMD) | Chief Financial Officer | $393,462 | $1,136,544 |
| 2021 | CorMedix Inc. (CRMD) | Executive Vice President and Chief Financial Officer | $351,923 | $1,423,302 |
| 2020 | CorMedix Inc. (CRMD) | Executive Vice President and Chief Financial Officer | $209,423 | $1,097,675 |
| 2019 | CorMedix Inc. (CRMD) | Chief Financial Officer | — | — |